Surgical Valve Replacement Might Soon Be History

Reference: Pierre Deharo et al. J Am Coll Cardiol 2020;76:489–99.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

Patients with dysfunctional biological prosthetic valves have better outcomes with TAVR vs. surgical reintervention, beyond surgical risk. This study outcomes might even call into question the age cutoff to consider a mechanical vs. a biological prosthesis at first surgery.

reoperación valvular

This analysis recently published in JACC looked at the outcomes of both possible strategies to treat a dysfunctional biological prosthesis, surgical reintervention and valve-in-valve.

It included 4327 patients in France with dysfunctional biological prosthesis between 2010 and 2019, which were compared using propensity score.

After matching, 717 with identical clinical and risk profile were left in each arm.

At 30 days, valve-in-valve was associated to lower end point rate, a combination of all cause death, stroke, MI and life-threatening major bleeding (OR: 0.62; CI 95%: 0.44 to 0.88; p=0.03). Up to this point, there were no big surprises, since a less invasive procedure will always have an acute benefit over a more aggressive one.


Read also: High Mortality Rates for Redo Surgery After TAVR.


At long term follow-up (mean 516 days) the combined end point (plus repeat hospitalization for cardiac failure) resulted similar between both arms (OR: 1.18; CI 95%: 0.99 s 1.41; p=0.26).

Repeat hospitalization for cardiac failure and pacemaker implantation were more frequent in the TAVR group.

Despite the latter, there was a clear interaction between all cause and cardiovascular mortality with valve-in-valve.


Read also: Is V-in-V the Treatment of Choice in Cases of Failed Biological Prosthesis?


These results are in line with the summary from the European Heart Journal we published on August 4, 2020.

Conclusion

Valve in valve is associated with better outcomes at short term and similar outcomes at long term vs. surgical reintervention in patients with dysfunctional biological prothesis in aortic position.  

Original Title: Transcatheter Valve-in-Valve Aortic Valve Replacement as an Alternative to Surgical Re-Replacement.

Reference: Pierre Deharo et al. J Am Coll Cardiol 2020;76:489–99.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

Can TAVI Be Safely Performed in Patients With Bicuspid Aortic Valve?

Bicuspid aortic valve (BAV) represents an anatomical challenge for transcatheter aortic valve replacement (TAVR) due to the frequent presence of elliptical annuli, fibroc calcific...

Transcatheter Paravalvular Leak Closure: Mid-Term Outcomes and Prognostic Factors

Paravalvular leaks (PVL) are a frequent complication following surgical valve replacement, occurring in 5% to 18% of prosthetic valves. Incidence varies according to valve...

After a Major Bleeding Event in Atrial Fibrillation: When Should Left Atrial Appendage Closure Be Considered?

Atrial fibrillation (AF) in patients who experience a major bleeding event represents a complex clinical scenario in which percutaneous left atrial appendage closure (LAAC)...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Valve-in-Valve in Small Surgical Aortic Bioprostheses: Balloon-Expandable or Self-Expanding? Three-Year Results from the LYTEN Trial

Dysfunction of small surgical aortic bioprostheses represents a challenging scenario for transcatheter aortic valve replacement in the valve-in-valve setting, due to the higher incidence...

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

How real are the adverse effects of statins? Evidence from randomized clinical trials

The safety of statins continues to be a subject of debate, partly due to the extensive list of adverse effects included in prescribing information,...